Intellia expects to incur charges of $8m associated with the reorganisation, which will likely be incurred in Q1 2025.

Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

The new Express License service removes barriers to accessing this transformative gene editing technology for startups.An ...

Scribe Therapeutics, co-founded by Jennifer Doudna, is reducing staff, the latest layoffs among companies focused on CRISPR ...

The core components of CRISPR-based genome-editing therapies are bacterial proteins called nucleases that can stimulate ...

Treatments for rare diseases are hard to create and expensive to deliver, but there is new hope for editing the software of ...

ON CRISPR enzyme, will combine with RNA guides for pharma customers. Deal follows HuidaGene agreement, offers 99% cost ...

Scribe announced its initial research collaboration with Sanofi for CRISPR-based cell therapies to address oncology ...

'Mad Money' host Jim Cramer weighs in on stock including: Lincoln Electric, Caesars Entertainment, CRISPR, and Seagate. This ...

Some of the best possible returns for investors come by not going after megacaps, but instead pursuing stocks that have more ...

Intellia Therapeutics is starting off 2025 with a significant head count reduction as it tosses out pipeline assets to keep ...

What I've learned from my work in this field is that having a well-crafted commercial strategy is important for companies ...